Clinton Group’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-75,509
Closed -$7.88M 556
2017
Q4
$7.88M Buy
+75,509
New +$8.52M 0.69% 36
2017
Q1
Sell
-2,944
Closed -$341K 1131
2016
Q4
$341K Sell
2,944
-79,746
-96% -$8.88M 0.02% 664
2016
Q3
$8.64M Sell
82,690
-10,011
-11% -$1.08M 0.4% 49
2016
Q2
$9.14M Buy
92,701
+61,571
+198% +$6.37M 0.4% 55
2016
Q1
$3.12M Buy
31,130
+2,200
+8% +$227K 0.19% 163
2015
Q4
$3.46M Buy
28,930
+3,982
+16% +$461K 0.28% 99
2015
Q3
$2.7M Buy
+24,948
New +$3.1M 0.25% 121
2015
Q2
Sell
-8,468
Closed -$976K 790
2015
Q1
$976K Buy
+8,468
New +$1.01M 0.25% 115
2014
Q2
Sell
-15,722
Closed -$1.1M 510
2014
Q1
$1.1M Buy
+15,722
New +$1.25M 0.41% 40

Other funds holding CELG

Clinton Group's CELG Position: Q1 2018 in Review

Clinton Group sold out of Celgene Corp (CELG) in Q1 2018, closing a stake of 75,509 shares — an estimated $7.88M sold.

Clinton Group first reported a position in CELG in Q1 2014 and held it in 9 quarters. The position peaked at $9.14M in Q2 2016. 1,397 funds tracked by Wall St. Rank hold CELG as of Q1 2018.

  • Clinton Group reported no remaining Celgene Corp position as of Q1 2018 after selling out during the quarter.
  • Clinton Group sold 75,509 Celgene Corp shares in Q1 2018, an estimated $7.88M.
  • Clinton Group first reported a position in Celgene Corp in Q1 2014 and held it in 9 quarters.
  • Clinton Group's Celgene Corp position peaked at $9.14M in Q2 2016.
  • 1,397 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2018.

Based on Clinton Group's 13F filing for Q1 2018, filed 14 May 2018.